BioVie to Present Phase 2 Sunrise-PD Trial Overview at the Advanced Therapeutics Congress
BioVie Inc. announced that a poster detailing the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical...
Inventprise’s COVID-19 Vaccine Breakthrough Published in Vaccine Journal
Inventprise, a clinical-stage vaccine company, published preclinical study results in Vaccine Journal demonstrating the potential of their bivalent SARS-CoV-2...
Actuate Therapeutics Reports Positive Phase 2 Elraglusib Trial Results in Metastatic Pancreatic Cancer
Actuate Therapeutics announced positive results from a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) as a first-line...
Enobosarm Reduces Weight Regain After Semaglutide
Veru Inc. announced positive topline results from the maintenance extension of its Phase 2b QUALITY clinical trial for enobosarm....
FDA Grants QRX003 Rare Pediatric Disease Designation for Netherton Syndrome
Quoin Pharmaceuticals announced that the FDA granted Rare Pediatric Disease Designation to QRX003 for treating Netherton Syndrome, a rare...
Pharmather Secures Key US Patent for Ketamine in ALS Treatment
PharmaTher Holdings Ltd. has been granted a U.S. patent for using ketamine to treat Amyotrophic Lateral Sclerosis (ALS), bolstering...
Dupixent® Approved for Bullous Pemphigoid Treatment
Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based...
Ajovy’s Effectiveness Reinforced in Real-World Migraine Prevention Study
The final analysis of the two-year PEARL study, presented at the 2025 European Academy of Neurology Congress, demonstrated the...
Enterome Reports Positive Results in Lymphoma Treatment
Enterome presented positive interim Phase 1/2 trial data for its OncoMimics™ immunotherapy, EO2463, in combination with lenalidomide and rituximab...
Dupixent® Approved for Bullous Pemphigoid Treatment
The FDA approved Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based on positive results from...